Teva Pharmaceutical Industries Limited
A maker of generic medicines, biosimilars, and brand-name drugs, Teva is one of the world's largest generic drugmakers. Its products treat conditions like multiple sclerosis (COPAXONE), migraine (AJOVY), and Huntington's chorea (AUSTEDO), used by patients and health systems worldwide. Founded in 1901 in Jerusalem as a small medicine wholesaler that shipped goods by mule and camel, it took the name "Teva"—the Hebrew word for "nature"—in the 1930s.
American Depositary Receipt (ADR) representing 1 ordinary share of Teva Pharmaceutical Industries Ltd
Granted 75.5K
Granted 681.9K
Granted 2.35M · Sold 1.18M
Granted 75.5K · Sold 1.13M
Granted 130.4K
Granted 244.4K · Sold 157.0K
Granted 384.0K · Sold 271.2K
Granted 75.5K
Granted 75.5K
Granted 75.5K
Granted 75.5K
Granted 440.6K · Sold 332.8K
Granted 6.7K
Granted 1.06M · Sold 1.04M
Granted 61.0K
Granted 73.2K
Granted 932.5K · Sold 885.3K
Granted 14.5K
Granted 185.7K · Sold 122.1K
Granted 14.5K
Granted 1.17M · Sold 1.13M
Granted 50.4K · Sold 5.3K
Granted 41.2K
Granted 85.8K · Sold 41.7K
Granted 22.5K
Granted 27.0K · Sold 20.2K
Granted 86.1K · Sold 97.2K
Granted 19.3K
Granted 16.7K · Bought 1.1K · Sold 4.8K
Granted 12.9K · Sold 4.1K
Granted 15.3K · Sold 5.1K
Granted 232.4K · Sold 232.4K
Granted 132.0K · Sold 177.3K
Granted 49.7K · Sold 49.7K
Granted 21.5K · Sold 21.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Elstein AmirDirector · 5 transactions | +3.7% | 2.12M | 75.5K | — | — |
| Schultz KarePresident and CEO, Director · 7 transactions | +79.2% | 1.54Mas of Nov 2022 | 681.9K | — | — |
| Francis Richard DPresident and CEO · 26 transactions | — | 1.18M | 2.35M | — | 1.18M |
| Mignone RobertoDirector · 10 transactions | -68.4% | 487.4K | 75.5K | — | 1.13M |
| Barer Sol JDirector · 5 transactions | +41.1% | 448.0K | 130.4K | — | — |
| Dethlefs SvenEVP, North America Commercial · 18 transactions | +112.1% | 165.4Kas of Mar 2023 | 244.4K | — | 157.0K |
| Drape EricExecutive VP Global Operations · 26 transactions | +340.5% | 145.9Kas of Mar 2024 | 384.0K | — | 271.2K |
| Lieberman Gerald MDirector · 5 transactions | +138.2% | 130.1K | 75.5K | — | — |
| Crane Rosemary ADirector · 5 transactions | +144.6% | 127.7K | 75.5K | — | — |
| Nisen PerryDirector · 5 transactions | +170.5% | 119.8K | 75.5K | — | — |
| Satchi-Fainaro RonitDirector · 5 transactions | +209.4% | 112.4K | 75.5K | — | — |
| Hughes Eric ASee "Remarks" · 23 transactions | — | 107.7K | 440.6K | — | 332.8K |
| Bergwerk DovActing Chief Legal Officer · 1 transaction | — | 97.0Kas of Feb 2024 | 6.7K | — | — |
| Sabag MarkSee "Remarks" · 33 transactions | +38.1% | 80.8K | 1.06M | — | 1.04M |
| Vergis Janet S.Director · 4 transactions | +481.8% | 73.7Kas of Jun 2025 | 61.0K | — | — |
| Zaks Tal ZviDirector · 6 transactions | — | 73.3K | 73.2K | — | — |
| Kalif Eliyahu SharonEVP, Chief Financial Officer · 32 transactions | +256.1% | 65.6K | 932.5K | — | 885.3K |
| Halfon Jean MichelDirector · 1 transaction | +29.4% | 63.7Kas of Jun 2022 | 14.5K | — | — |
| Fox ChristineEVP, U.S. Commercial · 13 transactions | — | 63.6K | 185.7K | — | 122.1K |
| Peres Nechemia JacobDirector · 1 transaction | +32.7% | 58.8Kas of Jun 2022 | 14.5K | — | — |
| Daniell RichardEVP, Europe Commercial · 60 transactions | +174.9% | 55.8K | 1.17M | — | 1.13M |
| Shani EliEVP,Global Marketing&Portfolio · 9 transactions | +496.5% | 54.2Kas of Mar 2023 | 50.4K | — | 5.3K |
| Inbar GaliaSee "Remarks" · 5 transactions | +853% | 46.0Kas of Mar 2023 | 41.2K | — | — |
| Lippman EvanEVP, Business Development · 4 transactions | — | 44.2K | 85.8K | — | 41.7K |
| Shalev VardaDirector · 2 transactions | — | 22.5Kas of Jun 2025 | 22.5K | — | — |
| Jover PlacidSee "Remarks" · 4 transactions | — | 20.9K | 27.0K | — | 20.2K |
| Weiss AmirChief Accounting Officer · 24 transactions | — | 20.0K | 86.1K | — | 97.2K |
| Lichtenstein ChenDirector · 2 transactions | — | 19.3K | 19.3K | — | — |
| McAvoy David R.EVP, Chief Legal Officer · 4 transactions | — | 13.0K | 16.7K | 1.1K | 4.8K |
| Grant AngusEVP, Business Development · 2 transactions | — | 12.9Kas of Aug 2024 | 12.9K | — | 4.1K |
| Savage BrianInterim Chief Legal Officer · 8 transactions | — | 10.9K | 15.3K | — | 5.1K |
| Stark David MatthewExec. VP Chief Legal Officer · 20 transactions | 0% | 3.0Kas of Mar 2023 | 232.4K | — | 232.4K |
| Fridriksdottir HafrunExecutive VP, Global R&D · 11 transactions | -96.7% | 1.4Kas of May 2022 | 132.0K | — | 177.3K |
| Shields MatthewEVP, Global Operations · 7 transactions | — | 0 | 49.7K | — | 49.7K |
| Conway Vikki LSee "Remarks" · 9 transactions | — | 0as of May 2024 | 21.5K | — | 21.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -6.90M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.